Table 1.
Characteristics of the patients treated with daily oral etoposide (median-range).
| Tumour type Number of patients (females) | Lung carcinoma n = 19 (2) | Hepatocellular carcinoma n = 17 (1) | Gastric cancer n = 5 (3) | Breast cancer n = 6 (6) | Others n = 3 (1) |
|---|---|---|---|---|---|
| Age (years) | 68 (54–80) | 65 (52–83) | 67 (60–78) | 63 (50–72) | 71 (68–73) |
| Performance status | 2 (0–3) | 1 (0–3) | 2 (2–3) | 2 (0–3) | 2 (0–2) |
| Pretreatment with 1 (2) regimens of chemotherapy | 11 (0) | 10 (0) | 4 (0) | 6 (4) | 2 (0) |
| Bone metastases | 3 | 0 | 0 | 5 | 1 |
| Baseline WBC (103/mm3) | 9.1 (6.8–17.0) | 6.0 (2.8–10.6) | 8.3 (4.3–14.0) | 7.0 (3.5–12.0) | 6.9 (5.7–8.2) |
| Creatinine clearance (ml min−1) | 66 (33–118) | 78 (30–121) | 55 (37–75) | 72 (22–113) | 44 (42–83) |
| Albumin (g dl−1) | 4.3 (3.6–4.9) | 3.8 (3.3–4.8) | 4.2 (3.5–4.7) | 3.8 (3.3–4.6) | 4.2 (3.5–4.6) |
| Bilirubin (mg dl−1) | 0.6 (0.5–1.1) | 1.9 (0.5–5) | 0.8 (0.6–1) | 0.7 (0.5–0.9) | 1 (0.9–2.7) |
| MEGX test (ng ml−1) | 61 (22–89) | 38 (10–70) | 49 (34–62) | 76 (30–160) | 81 (26–93) |